Clinical Trials - April 13, 2025
Orexo and Abera Bioscience announce positive data
The companies have announced positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology. The data was generated under the collaboration between Orexo and Abera Biosciences entered in December 2024. The aim of the collaboration is to develop mucosal vaccines by combining Orexo’s powder-based drug delivery technology AmorphOX with Abera’s […]
Clinical Trials - April 9, 2025
New clinical trial map launched in the EU
A new clinical trial map is now accessible from the public website of the Clinical Trials Information System (CTIS).
Clinical Trials - March 25, 2025
Immunovia provides further positive data from the VERIFI study
Immunovia has announced additional results from the VERIFI study of its next-generation pancreatic cancer test, strengthening the company’s position as it prepares to launch the pancreatic cancer blood test commercially.
Clinical Trials - March 18, 2025
Oncorena receives FDA approval to initiate studies in the US
The FDA has approved the company’s IND application to initiate the Phase I/II study Oncorella-1.
Clinical Trials - March 17, 2025
Anocca to start first in-human trial in advanced pancreatic cancer
The company has announced the authorization of its Clinical Trial Application (CTA) from the regulatory authorities in four European countries under the European Union’s (EU) harmonised framework, for VIDAR-1, with Germany acting as the reference state.
Clinical Trials - February 28, 2025
Evaxion extends phase 2 trial with personalized cancer vaccine
Evaxion Biotech will further enhance the data package from its ongoing phase 2 trial with the company’s lead asset EVX-01 by extending the trial from two to three years.
